Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2001 Nov 6;15(6):308–313. doi: 10.1002/jcla.1042

Performance characteristics of a transcription‐mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA

RS Ross 1,✉, SO Viazov 1, S Hoffmann 1, M Roggendorf 1
PMCID: PMC6807932  PMID: 11793430

Abstract

The detection of hepatitis C virus (HCV) RNA by nucleic acid amplification techniques is the method of choice to differentiate between ongoing and past infection, and can be used to monitor the course of HCV infection. In this study, we evaluated the performance characteristics of a newly developed transcription‐mediated amplification (TMA)‐based assay, the VERSANT® HCV RNA qualitative assay, which was designed to qualitatively detect HCV RNA. Samples tested by the TMA assay included 100 HCV antibody negative sera; serial dilutions of an HCV genotype 1a panel; the WHO HCV RNA standard 76/790; an HCV genotyping panel; and 150 clinical specimens, including sera from patients who had received α?interferon (IFN) treatment or liver transplants. TMA test results were compared with the Cobas Amplicor® HCV polymerase chain reaction (PCR) assay. The analytical specificity of the HCV?TMA assay was > 98%. No carry‐over contaminations were observed. The assay demonstrated an analytical sensitivity of 100% at 41 HCV RNA copies/mL (genotype 1a panel) and 5 IU/mL (WHO standard), respectively. HCV genotypes and subtypes did not affect the results. Qualitative RNA detection by diagnostic Amplicor® PCR and TMA was in agreement in > 97% of all 150 clinical samples tested. In our study, the TMA‐based assay proved to be a specific and sensitive method for qualitative HCV RNA detection. The test may turn out to be an attractive alternative to already established techniques for HCV?RNA amplification in routine clinical laboratories. J. Clin. Lab. Anal. 15:308–313, 2001. © 2001 Wiley‐Liss, Inc.

Keywords: hepatitis C virus, transcription‐mediated amplification, genotypes, new technology

REFERENCES

  • 1. Damen M, Cuypers HT. 1998. Detection of hepatitis C virus RNA: application to diagnostics and research In: Reesink HW, editor. Hepatitis C virus. Current studies in hematology and blood transfusion. Freiburg: Karger; p 76–106. [DOI] [PubMed] [Google Scholar]
  • 2. Schiff ER, De Medina M, Kahn RS. 1999. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis 19(Suppl 1):3–15. [PubMed] [Google Scholar]
  • 3. Shimotohno K, Feinstone SM. 1997. Hepatitis C virus and hepatitis G virus In: Richman DD, Whitely RJ, Hayden FG, editors. Clinical virology. New York: Churchill Livingstone; p 1187–1215. [Google Scholar]
  • 4. Albadalejo J, Alfonso R, Antinozzi R, et al. 1998. Multicenter evaluation of the Cobas Amplicor HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 36:862–865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Doglio A, Laffont C, Caroll‐Bosc FX, Rochet P, Lefebvre J‐C. 1999. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C RNA detection and yields results that are more clinically relevant. J Clin Microbiol 37:1567–1569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Gerken G, Pontisso P, Roggendorf M, et al. 1996. Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. J Hepatol 24:33–37. [DOI] [PubMed] [Google Scholar]
  • 7. Lunel F, Mariotti M, Cresta P, de la Croix I, Huraux J‐M, Lefrère JJ. 1995. Comparative study of conventional and novel strategies for the detection of hepatitis C virus RNA in serum: Amplicor, branched‐DNA, NASBA and in‐house PCR. J Virol Methods 54:159–171. [DOI] [PubMed] [Google Scholar]
  • 8. Mercier B, Burlot L, Ferec C. 1999. Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using TaqMan PCR assay. J Virol Methods 77:1–9. [DOI] [PubMed] [Google Scholar]
  • 9. Damen M, Sillekens P, Cuypers HT, Frantzen I, Melsert R. 1999. Characterisation of the quantitative HCV NASBA assay. J Virol Methods 82:45–54. [DOI] [PubMed] [Google Scholar]
  • 10. Hollingswood RC, Sillekens P, van Deursen P, Neal KR, Irving WL. 1996. Serum HCV RNA levels assessed by quantitative NASBA®: stability of viral load over time, and lack of correlation with liver disease. J Hepatol 25:301–306. [DOI] [PubMed] [Google Scholar]
  • 11. Lunel F, Cresta P, Vitour D, et al. 1999. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and Monitor assays. Hepatology 29:528–535. [DOI] [PubMed] [Google Scholar]
  • 12. Kwoh DY, Davis GR, Whitfield KM, Chapelle HL, DiMichelle LJ, Gingeras TR. 1989. Transcription‐based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead‐based hybridization format. Proc Natl Acad Sci U S A 86:1173–1177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Bayer Corporation . 1999. Target capture system operator’s manual.
  • 14. Collins ML, Zayati C, Detmer JJ, et al. 1995. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem 226:120–129. [DOI] [PubMed] [Google Scholar]
  • 15. Detmer J, Lagier R, Flynn J, et al. 1996. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched‐DNA technology. J Clin Microbiol 34:901–907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Hawkins A, Davidson F, Simmonds P. 1997. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assays versions 1 and 2, Roche Monitor assay, and an in‐house limiting dilution method. J Clin Microbiol 35:187–192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Saldanha J, Lelie N, Heath A. 1999. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO collaborative study group. Vox Sang 76:149–158. [DOI] [PubMed] [Google Scholar]
  • 18. Ross RS, Viazov S, Fiedler M, Roggendorf M. 1998. Plasma panel for standardisation of hepatitis C virus genotyping techniques. J Lab Med 22:673. [Google Scholar]
  • 19. Pawlotsky J‐M, Martinot‐Peignoux M, Poveda J‐D, et al. 1999. Quantification of hepatitis C virus RNA in serum by branched DNA‐based signal amplification. J Virol Methods 79:227–235. [DOI] [PubMed] [Google Scholar]
  • 20. Lu M, Funsch B, Wiese M, Roggendorf M. 1995. Analysis of hepatitis C virus quasispecies populations by temperature gradient gel electrophoresis. J Gen Virol 76:881–887. [DOI] [PubMed] [Google Scholar]
  • 21. Hoofnagle JH. 1998. Therapy of viral hepatitis. Digestion 59:563–578. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES